In almost every case, insurance does not cover stem cell therapy for knees. Private insurers, Medicare, Medicaid, and Tricare classify stem cell injections for knee osteoarthritis and other orthopedic conditions as experimental, investigational, or not medically necessary, and they deny the claims. Expect to pay the full cost yourself, generally $3,000 to $15,000 per knee.
Why Insurers Deny These Claims
The reason is regulatory. The FDA has stated that no regenerative medicine product is approved for treating orthopedic conditions, including osteoarthritis, tendonitis, knee pain, hip pain, or shoulder pain.1FDA.gov. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes The only FDA-approved stem cell products in the United States are blood-forming stem cells from umbilical cord blood, cleared exclusively for blood disorders such as leukemia and lymphoma. Anything a clinic markets for cartilage, tendons, or joint pain lacks FDA clearance.
Insurers require FDA approval plus large-scale clinical trial evidence before paying for a treatment. Stem cell knee therapy fails on both counts. Carriers also point to inconsistent preparation and injection protocols across clinics and the absence of evidence that these injections outperform cheaper, established options like physical therapy or corticosteroid shots.2California Pain. Regenerative Injection Therapy Insurance Coverage Guide
Where the Major Insurers Stand
Carrier policies differ in wording but not in outcome.
- Cigna classifies stem cell therapy as not medically necessary for all orthopedic and musculoskeletal conditions, including knee osteoarthritis, ligament and tendon repair, and cartilage repair.3Cigna. Medical Coverage Policy 0552 – Stem Cell Therapy
- Aetna labels adipose-tissue-derived injections, bone marrow-derived mesenchymal stromal cells for osteoarthritis, and PRP combined with stem cells (such as the Regenexx system) as experimental, investigational, or unproven. The procedure codes for knee osteoarthritis stem cell implants are explicitly listed as not covered.4Aetna. Blood and Adipose Tissue Derived Products for Selected Indications
- UnitedHealthcare calls autologous cellular therapy unproven and not medically necessary for all indications, citing low-quality evidence and no long-term outcome data for knee osteoarthritis.5UnitedHealthcare. Autologous Cellular Therapy Policy
- Blue Cross Blue Shield considers mesenchymal stem cell therapy investigational for all orthopedic uses. BCBS of North Carolina’s policy cites systematic reviews finding intra-articular stem cells offer “little to no pain relief for knee osteoarthritis.” The Federal Employee Program Blue Cross plan also does not cover these procedures.6Blue Cross NC. Orthopedic Applications of Stem Cell Therapy7FEP Blue. Orthopedic Applications of Stem Cell Therapy
Medicare does not cover stem cell injections for knees or any other joint. There is no National Coverage Determination for orthopedic stem cell applications, and no local Medicare Administrative Contractor has issued one either.8Providence Health Plan. Medical Policy MP372 – Stem Cell Therapy Medicare’s stem cell coverage is limited to hematopoietic stem cell transplants for blood cancers and related conditions.9Healthline. Medicare Stem Cell Therapy Medicaid takes the same position. Tricare does not cover stem cell therapy for orthopedic conditions, though it has offered provisional coverage for platelet-rich plasma injections for chronic mild-to-moderate knee osteoarthritis under specific conditions; that provisional PRP coverage was set to expire September 30, 2024, with any extension left to Tricare leadership.10TRICARE. TRICARE Policy Manual Chapter 13 Section 1.1
Related regenerative treatments fare no better. UnitedHealthcare classifies both PRP and prolotherapy as unproven and not medically necessary for any condition.11UnitedHealthcare. Prolotherapy and Platelet Rich Plasma Therapies One state has formally closed off workers’ compensation as a workaround: Washington’s Health Technology Clinical Committee voted 10-0 that stem cell therapy for musculoskeletal conditions is not a covered benefit, binding on the state’s Department of Labor and Industries.12Washington State HCA. Stem Cell Therapy for Musculoskeletal Conditions – Final Findings and Decision
What You Will Pay Without Insurance
In the United States, a single-knee stem cell injection generally runs between $3,000 and $15,000, averaging around $8,000. Add consultations, imaging, follow-up visits, and physical therapy, and a full course of treatment can reach $5,800 to $26,200.13OrthoRepair. Stem Cell Therapy Cost – A 2026 Price Guide for Knee Pain
Several factors push the price up or down. Autologous treatments using your own bone marrow or fat typically cost $5,000 to $15,000, while allogeneic (donor-derived) cell products run $3,000 to $10,000. Major metros charge 10 to 20 percent more than smaller markets, and clinics in Mexico or Colombia run 30 to 50 percent less than comparable U.S. providers.14StemConnect. Stem Cell Therapy for Knees Cost Treating both knees in one session usually costs 1.5 to 2 times the single-knee price.
Ways to Pay When Insurance Won’t
Patients paying out of pocket have a few options worth checking.
- HSA and FSA funds generally cover stem cell therapy, because the IRS defines deductible medical expenses to include “costs for treatments affecting any part or function of the body.” Confirm with your plan administrator and keep itemized receipts.15TaxCPE. Does Stem Cell Therapy Qualify as a Deductible Medical Expense
- Healthcare credit cards from companies such as CareCredit and Prosper Healthcare Lending offer 6- to 24-month terms, sometimes with deferred interest for qualified applicants.16OrthoRepair. Stem Cell Therapy Cost for Knees in 2026
- Clinic payment plans or cash-pay discounts of 5 to 10 percent are available at some providers for patients who pay in full at the time of service.17Denver Regenerative Medicine. Stem Cell Therapy Cost in Denver
- Tax deductions on Schedule A can apply to the treatment cost, subject to the standard threshold for medical expenses exceeding a percentage of adjusted gross income.15TaxCPE. Does Stem Cell Therapy Qualify as a Deductible Medical Expense
Services Around the Injection That May Still Be Covered
The injection itself is on you, but adjacent services often are not. An initial consultation with an orthopedic specialist can usually be billed as a standard office visit. X-rays and MRIs are frequently covered when they are medically necessary for diagnosis. Physical therapy prescribed after the procedure may also be covered under your plan, even though the stem cell procedure was out of pocket.16OrthoRepair. Stem Cell Therapy Cost for Knees in 2026 Workers’ compensation and employer or athletic program benefits occasionally cover a portion of these treatments, though many states and plans refuse.
Appealing a Denial
You can appeal, but the odds are poor because insurers deny these claims on policy grounds rather than case-specific medical necessity. Start by getting the exact reason for denial from the insurer’s letter. File an internal appeal with a letter of medical necessity from your treating physician, your medical records, imaging results, and documentation of conservative treatments you have already tried without success. If the internal appeal fails, you can request an independent external review. A complaint to your state insurance commissioner is a last option if you believe the denial was unfair.2California Pain. Regenerative Injection Therapy Insurance Coverage Guide
The structural problem is that overturning a blanket “experimental” determination is much harder than winning a case-specific medical necessity dispute. One case rarely moves a corporate coverage policy.
Is the Treatment Worth Paying For
The largest trial to date, the Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES), was published in Nature in March 2024. It enrolled 480 participants across four sites and compared three types of mesenchymal stem cells against standard corticosteroid injections. At one year, every group showed the same level of pain improvement. The stem cell injections were safe but did not outperform corticosteroids.18Duke Health. Stem Cell Therapy for Osteoarthritis Reviewed – MILES Study
That finding is the heart of the coverage debate. Dr. Blake Boggess, the principal investigator at the Duke site, said there is a “conflict of interest when these centers charge high prices for a treatment we now know doesn’t offer marked benefit over corticosteroids.” Corticosteroid shots are covered by insurance and cost a fraction of what stem cell clinics charge. Longer-term MILES data, including three-year results, is still being analyzed.18Duke Health. Stem Cell Therapy for Osteoarthritis Reviewed – MILES Study
Could Coverage Change
Coverage follows FDA approval, and the most advanced candidate is CARTISTEM, an umbilical cord blood-derived mesenchymal stem cell therapy from MEDIPOST. It has been approved in South Korea since 2012 for cartilage defects and completed a Phase 3 trial in Japan. In June 2026, MEDIPOST announced FDA agreement on a single pivotal Phase 3 study in the United States, with enrollment expected to begin in the first half of 2026, backed by a $140 million funding round closed in January 2026.19Clinical Trials Arena. MEDIPOST Files IND Amendment With FDA20PR Newswire. MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study
If CARTISTEM gets FDA approval through the Biologics License Application pathway, it would be the first stem cell product cleared for an orthopedic indication in the United States, and insurers would likely have to reconsider blanket denials for that specific indication. That approval, if it happens, is still years away. Several states, including Texas, Utah, Mississippi, and North Carolina, allow physicians to administer investigational stem cell therapies to patients with severe chronic or terminal conditions, but none of those laws require insurers to pay.21Rice University Baker Institute. Promoted Yet Unproven – How State Laws Expand Access to Unchecked Stem Cell Interventions
If you are weighing the spend today, hold the price tag against the MILES result: the leading trial found these injections performed no better than a corticosteroid shot your insurance already covers.